• Return to Headlines

Relatively High EBITDA Growth Detected in Shares of Allergan Plc in the Pharmaceuticals Industry (AGN, ANIP, LLY, SUPN, MRK)

By Amy Schwartz

Below are the three companies in the Pharmaceuticals industry with the highest EBITDA Growth (next year estimate vs. LTM). EBITDA Growth can be valuable in predicting future cash flow generation and earnings power.

Allergan Plc ranks highest with a EBITDA growth of 354.9%. Ani Pharmaceutic is next with a EBITDA growth of 90.3%. Eli Lilly & Co ranks third highest with a EBITDA growth of 60.9%.

Supernus Pharmac follows with a EBITDA growth of 59.4%, and Merck & Co rounds out the top five with a EBITDA growth of 58.9%.

SmarTrend is tracking the current trend status for Allergan Plc and will alert subscribers who have AGN in their portfolio or watchlist when shares have changed trend direction.

Keywords: highest ebitda growth allergan plc ani pharmaceutic eli lilly & co supernus pharmac Merck & Co

Ticker(s): AGN ANIP LLY SUPN MRK